Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

Journal for ImmunoTherapy of Cancer

Volumn 5, Issue 1, 2017, Pages

  Puzanov, I ^a   Diab, A ^b   Abdallah, K ^c   Bingham, C O ^d   Brogdon, C ^e   Dadu, R ^b   Hamad, L ^a   Kim, S ^b   Lacouture, M E ^f   LeBoeuf, N R ^g   Lenihan, D ^h   Onofrei, C ⁱ   Shannon, V ^b   Sharma, R ^a   Silk, A W ^l   Skondra, D ^j   Suarez Almazor, M E ^b   Wang, Y ^b   Wiley, K ^k   Kaufman, H L ^l   Ernstoff, M S ^a   Anderson, Jeff ^e   Lehman, Kimberly ^e   Reshef, Dan ^e   Saylors, Ann ^e   Turner, Michelle ^e   Waxman, Ian ^e   Arrindell, Deborah ^m   Andrews, Stephanie ⁿ   Ballesteros, Joan ^o   Boyer, Janie ^p   Cotarla, Ion ^p   Dawson, Michelle ^p   Goswami, Trishna ^p   Hayreh, Vinny ^p   Holmes, William ^p   Rasheed, Zeshaan ^p   Sarkeshik, Makan ^p   Schreiber, Judy ^p   Shafer Weaver, Kim ^p   Chen, Daniel ^q   Ley Acosta, Sergio ^q   Chonzi, David ^r   Go, William ^r   Cunha, Renato ^s   Gulley, James L ^s   Wood, Lauren ^s   Davies, Marianne ^t   Dicker, Adam ^u   Eifler, Lisa ^v   Gregory, Nancy ^v   Ferguson, Andrew ^w   Ferlini, Cristiano ^x   Frankel, Stanley ^y   Gochett, Celestine ^z   Goldberg, Jenna ^aa   Patel, Kiran ^aa   Wariabharaj, Darshan ^aa   Goncalves, Priscila ^s   Helie, Nicole ^d   Hsu, Jer Yuan ^ab   Ibrahim, Ramy ^ac   Larocca, Cecilia ^g   Lambotte, Olivier ^ad   Luke, Jason ^j   McClure, Joan ^ae   Michelon, Elisabete ^af   Nakamura, Mary ^ag   Piperdi, Bilal ^c   Riemer, Joanne ^ah   Robert, Caroline ^ai   Sharfman, William ^aj   Sharon, Elad ^s   Sherry, Richard ^s   Simonson, Cyndy ^ak   Thomas, Cherry ^al   Trehu, Elizabeth ^al   Thompson, John A ^am   Tresnan, Dina ^af   Zhang, Lin ^an   Zheng, Pan ^ao   more..

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e BRISTOL MYERS SQUIBB   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h WASHINGTON UNIVERSITY   (United States)

ⁱ INDIANA UNIVERSITY   (United States)

^j UNIVERSITY OF CHICAGO   (United States)

^k ONCOLOGY NURSING SOCIETY   (United States)

^l MASSACHUSETTS GENERAL HOSPITAL   (United States)

^m AMGEN INC   (United States)

ⁿ H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^o Vivia Biotech SL   (Spain)

^p ASTRAZENECA   (United Kingdom)

^q GENENTECH INC   (United States)

^r Kite Pharma Inc   (United States)

^s NATIONAL CANCER INSTITUTE   (United States)

^t YALE CANCER CENTER   (United States)

^u THOMAS JEFFERSON UNIVERSITY   (United States)

^v Prometheus Therapeutics and Diagnostics   (United States)

^w Gritstone Oncology Inc   (United States)

^x Hoffmann La Roche Ltd   (United States)

^y CELGENE CORPORATION   (United States)

^z KentuckyOne Health   (United States)

^aa Janssen Pharmaceuticals   (United States)

^ab NGM Biopharmaceuticals Inc   (United States)

^ac PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY   (United States)

^ad ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^ae National Comprehensive Cancer Network   (United States)

^af PFIZER INC   (United States)

^ag UNIVERSITY OF CALIFORNIA   (United States)

^ah JOHNS HOPKINS HOSPITAL   (United States)

^ai INSTITUT GUSTAVE ROUSSY   (France)

^aj JOHNS HOPKINS UNIVERSITY   (United States)

^ak (Un)Common Sense Solutions   (United States)

^al Jounce Therapeutics   (United States)

^am UNIVERSITY OF WASHINGTON   (United States)

^an EMD SERONO INC   (United States)

^ao CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

more..

Author keywords

Immune checkpoint inhibitor; Immune related adverse events; Toxicity

Indexed keywords

ANTIHISTAMINIC AGENT; CHECKPOINT KINASE INHIBITOR; CHIMERIC ANTIGEN RECEPTOR; CORTICOSTEROID; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HYDROCORTISONE; IMMUNOLOGIC AGENT; RHEUMATOID FACTOR; TROPONIN;

ANEMIA; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BLEPHARITIS; BRONCHOSCOPY; CANCER IMMUNOTHERAPY; CARDIOVASCULAR DISEASE; CLINICAL DECISION MAKING; COLITIS; DERMATITIS; DRUG INFUSION; ELECTROCARDIOGRAM; EPISCLERITIS; HEPATITIS; HORMONE SUBSTITUTION; HUMAN; HYPERTHYROIDISM; HYPOPHYSITIS; HYPOTHYROIDISM; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; MACULOPAPULAR RASH; MANAGEMENT; MEDICAL SOCIETY; MOTOR NEUROPATHY; NEPHRITIS; PNEUMONIA; POLYMERASE CHAIN REACTION; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PRURITUS; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SENSORY NEUROPATHY; THROMBOCYTOPENIA; THYROTOXICOSIS; TOXICITY; UVEITIS; WORKSHOP; CONSENSUS DEVELOPMENT; EVIDENCE BASED MEDICINE; IMMUNOTHERAPY; NEOPLASM; PRACTICE GUIDELINE; PROCEDURES; TOXICITY AND INTOXICATION;

CLINICAL DECISION-MAKING; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOTHERAPY; NEOPLASMS; NEUROTOXICITY SYNDROMES; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL;

EID: 85034749402     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/s40425-017-0300-z     Document Type: Article

References (104)

1. Hoos A. Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov. 2016;15(4):235-47.
2. Papaioannou NE, et al. Harnessing the immune system to improve cancer therapy. Ann Transl Med. 2016;4(14):261.
3. Administration, U.S.F.a.D. Drugs@FDA: FDA approved drug products. 2017 June 19th, 2017]; Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm.
4. Company, B.-M.S. Ipilimumab (Yervoy) Highlights of Prescribing Information. 2017 3/2017 [cited 2017 June 19th, 2017]; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125377s073lbl.pdf.
5. Company, B.-M.S. Nivolumab (Opdivo) Highlights of Prescribing Information. 2017 4/2017 [cited 2017 June 19th, 2017]; Available from: https://packageinserts.bms.com/pi/pi_opdivo.pdf.
6. Merck & Co., I. Pembrolizumab (Keytruda) Highlights of Prescribing Information. 2017 5/2017 June 19th, 2017]; Available from: https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf.
7. Genentech, I. Atezolizumab (Tecentriq) Highlights of Prescribing Information. 2017 4/2017 [cited 2017 June 19th, 2017]; Available from: https://www.gene.com/download/pdf/tecentriq_prescribing.pdf.
8. LP, A.P. Durvalumab (Imfinzi) Highlights of Prescribing Information. 2017 4/2017 [cited 2017 June 19th, 2017]; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761069s000lbl.pdf.
9. EMD Serono, I. Avelumab (Bavencio) Highlights of Prescribing Information. 2017 5/2017 [cited 2017 June 19th, 2017]; Available from: https://www.bavencio.com/en_US/document/Prescribing-Information.pdf.
10. Eggermont AM, et al. Prolonged survival in stage III melanoma with Ipilimumab adjuvant therapy. N Engl J Med. 2016;375(19):1845-55.
11. Bertrand A, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13:211.
12. Maughan BL, et al. Incidence of immune-related adverse events with program death Receptor-1- and program death Receptor-1 ligand-directed therapies in genitourinary cancers. Front Oncol. 2017;7:56.
13. Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res. 2015;4(5):560-75.
14. Topalian SL, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-54.
15. Kumar V, et al. Current diagnosis and Management of Immune Related Adverse Events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol. 2017;8:49.
16. Ascierto PA, et al. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2017;18(5):611-22.
17. Tarhini, A.A., et al., A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma (U.S. Intergroup E1609): Preliminary safety and efficacy of the ipilimumab arms. Journal of Clinical Oncology, 2017. 35(15_suppl): p. 9500-9500.
18. Lin Z, et al. PD-1 antibody monotherapy for malignant melanoma: a systematic review and meta-analysis. PLoS One. 2016;11(8):e0160485.
19. Collins LK, et al. Cutaneous adverse effects of the immune checkpoint inhibitors. Curr Probl Cancer. 2017;41(2):125-8.
20. Hua C, et al. Association of Vitiligo with Tumor Response in patients with metastatic melanoma treated with Pembrolizumab. JAMA Dermatol. 2016;152(1):45-51.
21. Prior, L.M., et al., Toxicities in immunotherapy: Can they predict response? J Clin Oncol, 2016. 34(15_suppl): p. e14534-e14534.
22. Johnson DB, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):1749-55.
23. Kwon ED, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15(7):700-12.
24. Hodi FS, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-23.
25. Ernstoff, M., et al., Challenges faced when identifying patients for combination immunotherapy. Future Oncology, 2017;153(11):1162-1165.
26. Pennock GK, Chow LQ. The evolving role of immune checkpoint inhibitors in cancer treatment. Oncologist. 2015;20(7):812-22.
27. Luke JJ, Ott PA. PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma. Oncotarget. 2015;6(6):3479-92.
28. Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51-60.
29. Derosa L R.B., Mezquita L, Naltet C, Enot D, Fidelle M, Goubet A-G, Soria JC, Massard C, Goldwasser F, Zitvogel L, Brosseau S, Escudier BJ, Loriot Y, Zalcman G, Besse B, Albiges L., Antibiotics prescription to decrease progression-free survival (PFS) and overall survival (OS) in patients with advanced cancers treated with PD1/PDL1 immune checkpoint inhibitors. J Clin Oncol. 2017;35(Supplement 6S; abstract 462).
30. Kaderbhai C, et al. Antibiotic use does not appear to influence response to Nivolumab. Anticancer Res. 2017;37(6):3195-200.
31. Weber JS, et al. Safety profile of Nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol. 2017;35(7):785-92.
32. Horvat TZ, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with Ipilimumab at memorial Sloan Kettering cancer center. J Clin Oncol. 2015;33(28):3193-8.
33. SERVICES., U.S.D.O.H.A.H., Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. 2010. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference:8.5x11.pdf.
34. Woodworth T, et al. Standardizing assessment and reporting of adverse effects in rheumatology clinical trials II: the rheumatology common toxicity criteria v.2.0. J Rheumatol. 2007;34(6):1401-14.
35. Immunotherapy, F.o.C.R.P.I.f.C. Streamlined Toxicity Management Guide_Working Draft_322.2017. 2017.
36. Belum VR, et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer. 2016;60:12-25.
37. Rivera N, et al. Hair Repigmentation during immunotherapy treatment with an anti-programmed cell death 1 and anti-programmed cell death ligand 1 agent for lung cancer. JAMA Dermatol. 2017;153(11):1162-1165.
38. Weber JS, Kähler KC, Hauschild A. Management of Immune-Related Adverse Events and Kinetics of response with Ipilimumab. J Clin Oncol. 2012;30(21):2691-7.
39. Weber JS. Practical management of immune-related adverse events from immune checkpoint protein antibodies for the oncologist. Am Soc Clin Oncol Educ Book. 2012:174-7. https://meetinglibrary.asco.org/record/66896/edbook.
40. Larkin J, et al. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23-34.
41. Weinstock C, et al. U.S. Food and Drug Administration approval summary: Atezolizumab for metastatic non-small cell lung cancer. Clin Cancer Res. 2017;23(16):4534-453.
42. Cramer P, Bresalier RS. Gastrointestinal and hepatic complications of immune checkpoint inhibitors. Curr Gastroenterol Rep. 2017;19(1):3.
43. Oble DA, et al. Alpha-CTLA-4 mAb-associated panenteritis: a histologic and immunohistochemical analysis. Am J Surg Pathol. 2008;32(8):1130-7.
44. Gupta A, et al. Systematic review: colitis associated with anti-CTLA-4 therapy. Aliment Pharmacol Ther. 2015;42(4):406-17.
45. Berman D, et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun. 2010;10:11.
46. Chen JH, et al. Histopathologic features of colitis due to immunotherapy with anti-PD-1 antibodies. Am J Surg Pathol. 2017;41(5):643-54.
47. Weber J, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res. 2009;15(17):5591-8.
48. Pompili M, et al. Tumor necrosis factor-alpha inhibitors and chronic hepatitis C: a comprehensive literature review. World J Gastroenterol. 2013;19(44):7867-73.
49. Lin MV, et al. The influence of anti-TNF therapy on the course of chronic hepatitis C virus infection in patients with inflammatory bowel disease. Dig Dis Sci. 2013;58(4):1149-56.
50. Kim KW, et al. Ipilimumab-associated colitis: CT findings. AJR Am J Roentgenol. 2013;200(5):W468-74.
51. Jain A, et al. Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis. World J Gastroenterol. 2017;23(11):2023-8.
52. Gonzalez RS, et al. PD-1 inhibitor gastroenterocolitis: case series and appraisal of 'immunomodulatory gastroenterocolitis'. Histopathology. 2017;70(4):558-67.
53. Kim KW, et al. Ipilimumab associated hepatitis: imaging and clinicopathologic findings. Investig New Drugs. 2013;31(4):1071-7.
54. Johncilla M, et al. Ipilimumab-associated hepatitis: Clinicopathologic characterization in a series of 11 cases. Am J Surg Pathol. 2015;39(8):1075-84.
55. Everett J, Srivastava A, Misdraji J. Fibrin ring granulomas in checkpoint inhibitor-induced hepatitis. Am J Surg Pathol. 2017;41(1):134-7.
56. Marthey L, et al. Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease. J Crohns Colitis. 2016;10(4):395-401.
57. Ryder M, et al. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer. 2014;21(2):371-81.
58. Weber JS, et al. Toxicities of immunotherapy for the practitioner. J Clin Oncol. 2015;33(18):2092-9.
59. Dadu R, Zobniw C, Diab A. Managing adverse events with immune checkpoint agents. Cancer J. 2016;22(2):121-9.
60. Faje A. Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. Pituitary. 2016;19(1):82-92.
61. Marie Joelle Pitteloud RD, Cabanillas ME, Shah K, Mimi I-Nan H, Habra MA, Waguespack SG, et al. Hypophysitis in the Age of Cancer Immunotherapy: Experience in a Large Cancer Center, in Endocrine Society's 97th Annual Meeting and Expo. San Diego: CA; 2015.
62. Corsello SM, et al. Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab. 2013;98(4):1361-75.
63. Blansfield JA, et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother. 2005;28(6):593-8.
64. Byun DJ, et al. Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol. 2017;13(4):195-207.
65. Johnson DB, et al. Survivorship in immune therapy: assessing chronic immune toxicities, health outcomes, and functional status among long-term Ipilimumab survivors at a single referral center. Cancer Immunol Res. 2015;3(5):464-9.
66. Weber JS, et al. Management of Adverse Events Following Treatment with Anti-Programmed Death-1 agents. Oncologist. 2016;21(10):1230-40.
67. Chamberlain JJ, et al. Diagnosis and Management of Diabetes: synopsis of the 2016 American Diabetes Association standards of medical Care in Diabetes. Ann Intern Med. 2016;164(8):542-52.
68. Naidoo J, et al. Pneumonitis in patients treated with anti-programmed Death-1/programmed death ligand 1 therapy. J Clin Oncol. 2017;35(7):709-17.
69. Khunger M, et al. Incidence of pneumonitis with use of PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials. Chest. 2017;152(2):271-281.
70. Wu J, et al. PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis. Sci Rep. 2017;7:44173.
71. Nishino M, et al. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2(12):1607-16.
72. Delaunay M, et al. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J. 2017;50(2). doi: 10.1183/13993003.00050-2017.
73. Lomax AJ, et al. Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: case series and immunophenotypic analysis. Int J Rheum Dis. 2017;20(9):1277-1285.
74. Vogel WV, et al. Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission. J Clin Oncol. 2012;30(2):e7-e10.
75. Andersen R, et al. Late development of splenic sarcoidosis-like lesions in a patient with metastatic melanoma and long-lasting clinical response to ipilimumab. Oncoimmunology. 2014;3(8):e954506.
76. Suarez-Almazor ME, et al. Review: immune-related adverse events with use of checkpoint inhibitors for immunotherapy of cancer. Arthritis Rheumatol. 2017;69(4):687-99.
77. Cappelli LC, et al. Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature. Arthritis Care Res (Hoboken). 2016;69(11):1751-1763.
78. Naidoo J, et al. Inflammatory arthritis: a newly recognized adverse event of immune checkpoint blockade. Oncologist. 2017;22(6):627-30.
79. Weber JS, et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol. 2013;31(34):4311-8.
80. Postow M W.J. Toxicities associated with checkpoint inhibitor immunotherapy. UpToDate 2017 [cited 2017 June 22nd, 2017]; available from: https://www.uptodate.com/contents/toxicities-associated-with-checkpoint-inhibitor-immunotherapy.
81. Gibney GT, et al. Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin Cancer Res. 2015;21(4):712-20.
82. Momtaz P, et al. Safety of infusing Ipilimumab over 30 minutes. J Clin Oncol. 2015;33(30):3454-8.
83. Bird BR, Swain SM. Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res. 2008;14(1):14-24.
84. Lurz P, et al. Diagnostic performance of CMR imaging compared with EMB in patients with suspected myocarditis. JACC Cardiovasc Imaging. 2012;5(5):513-24.
85. Heinzerling L, et al. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer. 2016;4:50.
86. Shiuan E, et al. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy. J Immunother Cancer. 2017;5:8.
87. Hopkins AM, et al. Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers. Br J Cancer. 2017;117(7):913-20.
88. Michot JM, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139-48.
89. Cortazar FB, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int. 2016;90(3):638-47.
90. Wanchoo R, et al. Adverse renal effects of immune checkpoint inhibitors: a narrative review. Am J Nephrol. 2017;45(2):160-9.
91. Escandon J, et al. Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor. J Immunother Cancer. 2017;5:3.
92. Boutros C, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol. 2016;13(8):473-86.
93. Rizvi NA, et al. Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2016;34(25):2969-79.
94. Fadel F, El Karoui K, Knebelmann B. Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med. 2009;361(2):211-2.
95. Izzedine H, et al. Kidney injuries related to ipilimumab. Investig New Drugs. 2014;32(4):769-73.
96. Thajudeen B, et al. Ipilimumab granulomatous interstitial nephritis. Am J Ther. 2015;22(3):e84-7.
97. Kaufman HL, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17(10):1374-85.
98. Cuzzubbo S, et al. Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer. 2017;73:1-8.
99. Hottinger AF. Neurologic complications of immune checkpoint inhibitors. Curr Opin Neurol. 2016;29(6):806-12.
100. Bricout M, et al. Vogt-Koyanagi-Harada-like syndrome complicating Pembrolizumab treatment for metastatic melanoma. J Immunother. 2017;40(2):77-82.
101. Matsuo T, Yamasaki O. Vogt-Koyanagi-Harada disease-like posterior uveitis in the course of nivolumab (anti-PD-1 antibody), interposed by vemurafenib (BRAF inhibitor), for metastatic cutaneous malignant melanoma. Clin Case Rep. 2017;5(5):694-700.
102. Papavasileiou E, et al. Ipilimumab-induced ocular and orbital inflammation--a case series and review of the literature. Ocul Immunol Inflamm. 2016;24(2):140-6.
103. Pages C, et al. Ipilimumab-induced acute severe colitis treated by infliximab. Melanoma Res. 2013;23(3):227-30.
104. Tripathi A, et al. Programmed cell death-1 pathway inhibitors in genitourinary malignancies: specific side-effects and their management. Curr Opin Urol. 2016;26(6):548-55.